| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H30O3 |
| Molecular Weight | 366.4932 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C5=CC(=O)CC[C@]35C)[C@@H]1[C@@H]6C[C@@H]6[C@]27CCC(=O)O7
InChI
InChIKey=METQSPRSQINEEU-BCOSXLPSSA-N
InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24-/m1/s1
| Molecular Formula | C24H30O3 |
| Molecular Weight | 366.4932 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
17-epidrospirenone is a derivative of drospirenone with a reversed configuration of the 17-spirolactone ring had no biological activity. Drospirenone impurity. Drospirenone is a synthetic progestational compound used as a component of oral contraceptive in combination with ethinyl estradiol.
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
